Cargando…
Pre-Clinical Evaluation of the Nanoliposomal antiPCSK9 Vaccine in Healthy Non-Human Primates
Background: Our previous studies showed the safe preventive and therapeutic effects of immunization using the nanoliposomal antiPCSK9 vaccine called “Liposomal Immunogenic Fused PCSK9-Tetanus plus Alum adjuvant” (L-IFPTA), in mouse models of atherosclerosis. Here we aimed to ascertain the immunogeni...
Autores principales: | Momtazi-Borojeni, Amir Abbas, Jaafari, Mahmoud R., Banach, Maciej, Gorabi, Armita Mahdavi, Sahraei, Hedayat, Sahebkar, Amirhossein |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8309966/ https://www.ncbi.nlm.nih.gov/pubmed/34358164 http://dx.doi.org/10.3390/vaccines9070749 |
Ejemplares similares
-
Potential anti-tumor effect of a nanoliposomal antiPCSK9 vaccine in mice bearing colorectal cancer
por: Momtazi-Borojeni, Amir Abbas, et al.
Publicado: (2019) -
Therapeutic effect of nanoliposomal PCSK9 vaccine in a mouse model of atherosclerosis
por: Momtazi-Borojeni, Amir Abbas, et al.
Publicado: (2019) -
PCSK9 immunization using nanoliposomes: preventive efficacy against hypercholesterolemia and atherosclerosis
por: Momtazi-Borojeni, Amir Abbas, et al.
Publicado: (2021) -
Retraction Note: Therapeutic effect of nanoliposomal PCSK9 vaccine in a mouse model of atherosclerosis
por: Momtazi-Borojeni, Amir Abbas, et al.
Publicado: (2023) -
Impact of PCSK9 Immunization on Glycemic Indices in Diabetic Rats
por: Momtazi-Borojeni, Amir Abbas, et al.
Publicado: (2021)